Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating activities:
Net loss	$ (110,559)	$ (182,024)
Adjustments to reconcile net loss to net cash used for operating activities:
Stock-based compensation expense	32,854	42,980
Depreciation and amortization	2,899	2,889
Amortization of debt discount	133
Amortization of debt issuance costs	206	202
Accretion of discount on short-term investments	(1,739)	(736)
Impairment of property and equipment	617	209
Loss on disposal of property and equipment	10	74
Change in operating assets and liabilities:
Accounts receivable	(8,088)	(16,550)
Inventory	12,463	(6,191)
Prepaid expenses and other assets	15,426	1,010
Accounts payable	15	(578)
Accrued clinical and manufacturing liabilities	(2,177)	752
Accrued payroll and employee liabilities	(4,192)	(1,847)
Other accrued liabilities	3,343	12,898
Net cash used in operating activities	(58,789)	(146,912)
Investing activities:
Purchases of short-term investments	(87,658)	(145,683)
Maturities and sales of short-term investments	107,185	143,957
Purchases of property and equipment	(1,545)	(1,825)
Proceeds from the sale of property and equipment	13	227
Net cash provided by (used in) investing activities	17,995	(3,324)
Financing activities:
Net proceeds from sale of common stock	29,755	75,145
Net proceeds from notes financing	24,350
Proceeds from purchases under the Employee Stock Purchase Plan	904	1,444
Payments for stock issued under the equity incentive plan	(903)	(1,530)
Proceeds from warrant exercises	1
Net cash provided by financing activities	54,107	75,059
Net increase (decrease) in cash and cash equivalents	13,313	(75,177)
Cash and cash equivalents at beginning of year	15,364	90,541
Cash and cash equivalents at end of year	28,677	15,364
Supplemental disclosure of cash flow information:
Interest paid	$ 3,059	$ 2,250